Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

por Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, Germing, U
Publicado 2013

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

por Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Publicado 2008

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an...

por Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Publicado 2008